Evidence map›Paper›PMID 35117685›Full record

ArticleTranslational cancer research2020

Drug-eluting beads-transcatheter arterial chemoembolization with or without iodine-125 treatment is effective and tolerable in treating advanced non-small cell lung cancer patients: a pilot study.

Zhongwei Zhao, Jianfei Tu, Xiaoxi Fan, Jingjing Song, Fazong Wu, Xihui Ying, Jianting Mao, Jiansong Ji

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhongwei Zhao *Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui 323000, China.
Jianfei Tu *Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui 323000, China.
Xiaoxi FanKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui 323000, China.
Jingjing SongKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui 323000, China.
Fazong WuKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui 323000, China.
Xihui YingKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui 323000, China.
Jianting MaoKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui 323000, China.
Jiansong JiKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui 323000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to explore the efficacy and safety of drug-eluting beads-transcatheter arterial chemoembolization (DEB-TACE) with or without iodine-125 (

methodsA total of 25 advanced NSCLC patients underwent DEB-TACE were consecutively enrolled, among which 17 cases also received

resultsZero (0.0%), 13 (54.2%), 9 (37.5%) and 2 (8.3%) patients realized complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) respectively, and the objective response rate (ORR) and disease control rate (DCR) were 54.2% and 91.7%. The median OS was 12.6 (95% CI: 7.8-17.5) months. No difference of treatment response or OS was observed between DEB-TACE treatment alone and DEB-TACE plus

conclusionsDEB-TACE with or without

Indexed as

Drug-eluting beads-transcatheter arterial chemoembolization (DEB-TACE)non-small cell lung cancer (NSCLC)overall survival (OS)safety profilestreatment response

Identifiers

PMID35117685
PMCPMC8798642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.